Trial Profile
Study of dabigatran users compared with other direct oral anticoagulant (DOACs) in patients with atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Apixaban; Rivaroxaban
- Indications Thrombosis
- Focus Adverse reactions
- 03 Dec 2018 New trial record
- 15 Nov 2018 Results published in the Pharmacoepidemiology and Drug Safety